Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes m...
Journal Information
Vol. 154. Issue 5.
Pages 171-174 (March 2020)
Share
Share
Download PDF
More article options
ePub
Visits
28
Vol. 154. Issue 5.
Pages 171-174 (March 2020)
Brief report
Effect of dapagliflozin on arterial stiffness in patients with type 2 diabetes mellitus
Efecto de dapagliflozina sobre la rigidez arterial en pacientes con diabetes mellitus tipo 2
Visits
...
Juan Carlos Hidalgo Santiagoa, Juan Maraver Delgadob, Manuel Cayón Blancoc, Juan Bosco López Saezd, Pablo Gómez-Fernándezb,
Corresponding author
pgomezf@senefro.org

Corresponding author.
a Centro de Salud San Telmo, Jerez de la Frontera, Cádiz, Spain
b Unidad de Factores de Riesgo Vascular, Hospital Universitario del SAS, Jerez de la Frontera, Cádiz, Spain
c Endocrinología, Hospital Universitario del SAS, Jerez de la Frontera, Cádiz, Spain
d Facultad de Medicina, Universidad de Cádiz, Cádiz, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Values of haematological and biochemical parameters in baseline blood and urine, at 6 and 12 months.
Abstract
Introduction

Oral antidiabetic inhibitors of the sodium-glucose cotransporter (SGLT2i) reduce cardiovascular morbidity and mortality in DM2. The increase in arterial stiffness can participate in this morbidity and mortality. The aim of this study was to analyse the effect of the administration of dapagliflozin on arterial stiffness.

Patients and methods

Prospective observational study that included 32 patients with DM2. Before starting dapagliflozin, and at 6 and 12 months, biochemical parameters in blood and urine were analysed. Before starting dapagliflozin and at 12 months the velocity of the carotid-femoral pulse (VPc-f) was determined by tonometry. Changes in the variables and their interrelation was analysed by repeated data ANOVA, Wilcoxon's test and multiple regression.

Results

A significant decrease in the VPc-f was observed. There was no association between decreased VPc-f and changes in blood glucose, uric acid, blood pressure or weight.

Conclusions

Dapagliflozin, in subjects with DM2, produces a medium to long-term decrease in arterial stiffness.

Keywords:
Diabetes mellitus
Arterial stiffness
Dapagliflozin
Resumen
Introducción y objetivos

Los antidiabéticos orales inhibidores del cotransportador sodio-glucosa (iSGLT2) reducen la morbimortalidad cardiovascular en la DM2. El aumento de la rigidez arterial puede participar en esta morbimortalidad. El objetivo de este trabajo fue analizar el efecto de la administración de dapagliflozina en la rigidez arterial.

Pacientes y métodos

Estudio observacional, prospectivo que incluyó 32 pacientes con DM2. Antes del inicio de dapagliflozina y a los 6 y 12 meses se analizaron parámetros bioquímicos en sangre y orina. Basalmente y a los 12 meses se determinó la velocidad de pulso carótida-femoral (VPc-f) mediante tonometría. El análisis de los cambios en las variables y su interrelación se hizo mediante ANOVA de datos repetidos, test de Wilconson y regresión múltiple.

Resultados

Se objetivo un descenso significativo de la VPc-f. No se evidenció asociación entre descenso de VPc-f y cambios de la glucemia, uricemia, presión arterial ni del peso.

Conclusiones

Dapagliflozina, en sujetos con DM2, produce a medio-largo plazo, una disminución de la rigidez arterial.

Palabras clave:
Diabetes mellitus
Rigidez arterial
Dapagliflozina

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos